Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Significant Drop in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a significant decrease in short interest in June. As of June 30th, there was short interest totaling 16,698 shares, a decrease of 38.7% from the June 15th total of 27,250 shares. Approximately 1.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 39,560 shares, the short-interest ratio is presently 0.4 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on BOLT shares. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Monday, April 20th. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. Finally, Rodman & Renshaw began coverage on Bolt Biotherapeutics in a research note on Thursday, May 28th. They set a “buy” rating and a $22.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $34.67.

Bolt Biotherapeutics Trading Down 1.8%

Shares of BOLT traded down $0.07 during mid-day trading on Friday, reaching $4.12. 1,928 shares of the company were exchanged, compared to its average volume of 26,269. The business has a 50 day simple moving average of $4.47 and a two-hundred day simple moving average of $4.88. The company has a debt-to-equity ratio of 0.98, a quick ratio of 3.51 and a current ratio of 3.51. The stock has a market capitalization of $7.90 million, a PE ratio of -0.25 and a beta of 1.16. Bolt Biotherapeutics has a 52 week low of $3.75 and a 52 week high of $7.20.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Tuesday, May 12th. The company reported ($4.31) EPS for the quarter, missing the consensus estimate of ($2.85) by ($1.46). Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 100.89%. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $1.50 million. On average, analysts predict that Bolt Biotherapeutics will post -11.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bolt Biotherapeutics

Large investors have recently modified their holdings of the company. Renaissance Technologies LLC lifted its stake in shares of Bolt Biotherapeutics by 40.3% in the 1st quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock valued at $312,000 after purchasing an additional 22,200 shares during the period. T3 Companies LLC acquired a new stake in Bolt Biotherapeutics during the fourth quarter worth approximately $208,000. Nano Cap New Millennium Growth Fund L P bought a new stake in Bolt Biotherapeutics in the fourth quarter worth approximately $112,000. Susquehanna International Group LLP bought a new stake in Bolt Biotherapeutics in the third quarter worth approximately $89,000. Finally, Shay Capital LLC acquired a new position in Bolt Biotherapeutics in the third quarter valued at approximately $85,000. 86.70% of the stock is currently owned by institutional investors and hedge funds.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.